A
9.74
-0.38 (-3.75%)
| Previous Close | 10.12 |
| Open | 9.95 |
| Volume | 189,200 |
| Avg. Volume (3M) | 885,366 |
| Market Cap | 359,408,608 |
| Price / Sales | 15.50 |
| Price / Book | 47.14 |
| 52 Weeks Range | |
| Earnings Date | 8 Aug 2025 - 22 Aug 2025 |
| Operating Margin (TTM) | -1,220.88% |
| Diluted EPS (TTM) | -1.62 |
| Quarterly Revenue Growth (YOY) | 118.00% |
| Total Debt/Equity (MRQ) | 106.83% |
| Current Ratio (MRQ) | 1.41 |
| Operating Cash Flow (TTM) | -51.82 M |
| Levered Free Cash Flow (TTM) | -30.61 M |
| Return on Assets (TTM) | -32.84% |
| Return on Equity (TTM) | -103.19% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Adlai Nortye Ltd. | Mixed | Mixed |
AIStockmoo Score
0.6
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 4.0 |
| Average | 0.63 |
|
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 14.25% |
| % Held by Institutions | 0.18% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Feb 2026 | Announcement | Adlai Nortye Announces $140.0 Million Private Placement Equity Financing |
| 29 Dec 2025 | Announcement | Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China |
| 21 Nov 2025 | Announcement | Adlai Nortye to Participate in Upcoming Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |